Newsroom
Counterfeit MabThera Found in Germany
Following Herceptin earlier this year, Roche has announced that tampered vials of it's blood cancer drug MabThera (Rituxan) were found in Germany.
Gilead’s New Hepatitis C Drug Will Cost More
Despite the current high cost of Gilead Science’s hepatitis C drug, the next generation version will be even more expensive. However, the company also struck deals with generic drugmakers to bring the drug to developing countries.
Payers Restrict Coverage for Proton Radiation Therapy
Weighing the cost-benefit ratio of proton radiation therapy, private and public payers are placing coverage limitations on the use of this treatment.
HHS Awards $295 Million in Funding to Expand Primary Care Services
More than 1,000 health centers in every US state and territory will receive Affordable Care Act funds to expand their primary care services, according to an announcement from Health and Human Services' Secretary Sylvia M. Burwell.
To Treat or Not to Treat: The Overdiagnosis Debate
Rapid advances in detection technology, coupled with an increased awareness about screening, have ignited a debate on overdiagnosis and overtreatment of precancerous lesions. Should physicians use their discretion and implement a "wait-and-watch" approach?
In The Literature: MicroRNA Biomarkers Could Predict Chemotherapy Response in Lung Cancer
MicroRNAs have the potential to be predictive biomarkers that can predict survival as well as response to chemotherapy, as this study discovered.
PCORI Announces Pilot Projects Program Awards Recipients
The Patient-Centered Outcomes Research Institute (PCORI) has announced the approval of 50 research funding awards, totaling $30 million over two years, through its Pilot Projects Program, which will address a broad range of questions about methods for engaging patients in the health research and dissemination process.
GLP-1 Agonists With Insulin Yield Remarkable Results
A meta-analysis published in The Lancet found that the combination was most successful in achieving the target A1C, with a minimal risk of hypoglycemia and weight loss.
CMS's Open Payments Database on Schedule for Launch
Despite reported glitches, CMS plans to launch the database that will provide information on payments for research, gifts, meals, or speaker fees received by providers and teaching hospitals from the pharmaceutical industry.
Advocate, NorthShore Merger Will Create Illinois’ Largest Healthcare System
A newly announced merger between Advocate Health Care and NorthShore University HealthSystem will create Illinois’ largest integrated healthcare delivery system, serving 3 million patients annually.
Rise of Retail Health Exchanges Could Heavily Impact Insurance Industry
Retail health insurance marketplaces, also known as exchanges, are on the cusp of dramatically changing the health insurance business, according to a new report from PwC’s Health Research Institute.
Merck Serono to Halt Stage III NSCLC Trial With Tecemotide
Tecemotide, a synthetic lipopeptide immunotherapy was being developed as a cancer vaccine against the MUC1 glycoprotein that is often aberrantly overexpressed in NSCLC.
In The Literature: MicroRNAs As Markers of Cancer Risk, Based on Ethnicity
The study, published in BMC Medical Genomics, identified ethnicity-based variability in microRNA expression that could lead to health disparities in cancer across the globe.
Study Evaluating Clinical Trial Bias in Pharma Presents Encouraging Evidence
The study, which evaluated the top 20 pharmaceutical companies, identified Amgen, AstraZeneca, and Celgene as the most dedicated to clinical trial data sharing.
GNS Healthcare Appoints AJPB Editor Jan Berger, MD, to Board
GNS Healthcare, a leading provider of big data analytics in health care, today announced the appointment of Jan Berger, MD, MJ, to its board of directors. Berger, who served CVS Caremark as chief clinical officer for nearly 10 years, is an internationally recognized expert in medication adherence and value-based health care. She is currently president and CEO of Health Intelligence Partners, a consultancy providing business strategies and solutions to clients across the care continuum.
NanoString Announces New PanCancer Immune Panel
The panel, developed in collaboration with immunooncology scientists around the world, including at INSERM, will help researchers create a profile of the human immune response in all cancer types.
Addressing Health Technology Barriers for Baby Boomers
Although baby boomers are expected to place a large burden on healthcare resources, consumer health technologies could help stem increasing needs and costs, according to a new study in the Journal of Medical Internet Research.
Extended Use of Xtandi in Chemothrerapy-Naïve Prostate Cancer Patients
The FDA approval will greatly influence the reach of the drug which was approved for use in advanced prostate cancer patients.
US Hospital Administrative Costs Exceed Comparable Countries
An analysis of hospital administrative costs across 8 countries found hospital bureaucracy accounts for a quarter of hospital spending in the United States.
Grant Rewards Insights Into State Healthcare Reform Implementation
The Health Care Cost Institute and the National Academy for State Healthy Policy are launching a grant program to fund studies that will analyze how the states are implementing health reform.
ONC Revises 2014 EHR Certification
The Office of the National Coordinator for Health IT released a final rule for electronic health record certification that offers more flexibility for health information technology developers, providers, and consumers.
Watchful Waiting in Prostate Cancer: Role of Ethnicity
The retrospective study, conducted at the Thomas Jefferson University in Philadelphia, found that watchful waiting among black men with early stage prostate cancer who had undergone surgery, resulted in a more aggressive disease.
Young Adult ED Use Decreased Under ACA Provision
Extending young adults’ eligibility for health insurance on their parents’ plans under an Affordable Care Act provision led to a decrease in emergency department visits.
AACR's Policy Statement Urges FDA-Regulation of Laboratory-Developed Tests
The statement points to the increased complexity of some of the LDTs and highlights patient safety issues that are at stake.